| abstract |
The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675,206 (11.2.1), and ipilimumab, in combination with a therapeutic agent for treatment of cancer. An exemplary method of the invention comprises administering an anti-CTLA4 antibody, preferably, CP-675,206, and a chemotherapeutic agent, preferably, gemcitabine, for treatment of pancreatic cancer, among other treatment modalities. |